



SideROS

TACKLE RELAPSE & METASTASIS IN CANCER

International Cancer Cluster Showcase BIO, 2020

SideROS aims to tackle relapse and metastasis by targeting persister cancer cells with small molecules



SideROS

Co-founded in January 2019
by Raphaël Rodriguez

Target persister cancer cells with a small molecules, the ironomycin and eliminate them through a ferroptosis mechanism.

Co-founder, SAB Chairman & Scientific advisor



Raphaël Rodriguez, PhD, HDR

Director of research, CNRS/Curie Institute, internationally recognized in translational chemistry/biology

Chief Executive Officer



Lucie Mondoulet, PhD, HDR

11 years experience in biotechnology at the direction of R&D department from discovery to clinical program

Business Development Advisor



Nathalie Donne, MSc, eMBA

15 years experience in biotechnology at the direction of BD & alliance management department

Global Development Advisor



Laurent Martin, PharmD, MBA

25 years experience in Pharma & biotechnology at the direction of regulatory affairs and global development department




COLLÈGE
DE FRANCE
—1530—

i-Lab

INSTITUT DE FRANCE
FONDATION CHARLES DEFFOREY
(ANCIENNE FONDATION LOUIS D.)

*Prix
Lacassagne*

La FRENCH
TECH
bpjfrance



Young
Investigator
Award

ROYAL SOCIETY
OF CHEMISTRY

Biofit FOSTERING
INNOVATION
& TRANSFER

eit
Health


RISE
CNRS
INNOVATION

Targeting iron metabolism with ironomycin to prevent relapse and metastasis

Relapse and Metastasis are :



- correlated to low survival rate,
- related to persister cancer cells viability & metabolism.

Iron in cancer cells



→ Persister cancer cells are iron dependent

→ Disturbing iron metabolism can eradicate persister cancer cells





→ Only ironomycin prevents tumor seeding

3 years development plan for ironomycin, from non-clinical PoC to phase 1 basket trial

Ironomycin, chemistry & applications protected by 3 patents **exclusively licensed** to SideROS




Synthesis in 2 steps



Patient benefit of ironomyacin combined treatment


High iron score expressed in **patient cells** at diagnosis, undergoing **relapse after frontline treatment** (R-CHOP)

Lenz R-CHOP cohort




N = 233

Melnick R-CHOP cohort



N = 69


FFPE R-CHOP cohort



N = 72

In versatile indications in cancer, such as DLBCL, **ironomyacin should be used in combination to frontline treatment to eradicate whole tumor AND prevent relapse and metastasis.**

A mixed business model to accelerate SideROS development until NDA/MA approval showing our partnership objectives & opportunities





SideROS

Contact:

Lucie Mondoulet, CEO

lucie.mondoulet@sideros.bio

+33 6 62 59 04 17